Due to the lower risk of cancer compared to the other genes, many PMS2 families likely did not fulfil the original or revised Amsterdam or Bethesda criteria for testing [6], and thus were not identified when these criteria were used to select patients for testing [6, 7]. The gene discussed is PMS2; the disease is cancer.